Abstract：【Objective】To explore the efficacy of Zishen Runfeifang in combined with chemotherapy in patients with advanced lung cancer exhibiting both Qi and Yin deficiencies.【Methods】Eighty patients with advanced lung cancer exhibiting both Qi and Yin deficiencies, who received treatment in our two hospitals, were randomly divided into a chemotherapy group and a combination group, with 40 patients in each group. The chemotherapy group received conventional lung cancer chemotherapy, while the combination group received Zishen Runfeifang orally in addition to the chemotherapy. The efficacy, time to disease progression (TTP), 1-year survival rate, 1-year progression-free survival (PFS) rate, improvements in Traditional Chinese Medicine symptom scores, and Karnofsky Performance Scale (KPS) scores before and after treatment, as well as the occurrence of bone marrow suppression, were compared between the two groups.【Results】The total effective rate (RR) in the combination group was 37.5% (15/40) and the disease control rate (DCR) was 82.5% (33/40), whereas the chemotherapy group had an RR of 27.5%(11/40) and a DCR of 70.0%(28/40). The differences between the groups were not statistically significant(P>0.05). The TTP in the chemotherapy group was 6.5(4.2-8.4) months, with a 1-year survival rate of 30.0%(12/40), and a 1-year PFS rate of 85.0%(34/40); the combination group had a TTP of 7.2(5.5-9.3) months, a 1-year survival rate of 35.0%(14/40), and a 1-year PFS rate of 87.5%(35/40). The differences between the two groups were not statistically significant(P>0.05). Compared to before treatment, both groups showed a significant reduction in Traditional Chinese Medicine symptom scores after treatment, with more significant reductions in the combination group(P<0.05). After treatment, the stability rate of KPS scores in the combination group was 90.00%(36/40), significantly higher than the 70.00%(28/40) in the chemotherapy group(P< 0.05). The total occurrence rate of bone marrow suppression in the combination group was 17.5%(7/40), lower than 42.5%(17/40) in the chemotherapy group.【Conclusion】Zishen Runfeifang combined with chemotherapy can effectively improve patients' quality of life and reduce the occurrence rate of bone marrow suppression.
徐华智, 李宁, 马一杰. 滋肾润肺方辅助化疗治疗中晚期肺癌气阴两虚证患者的临床疗效[J]. 医学临床研究, 2024, 41(5): 718-721.
XU Huazhi, LI Ning, MA Yijie. The Effect of Zishen Runfeifang in Combined with Chemotherapy on Clinical Efficacy with Advanced Lung Cancer Exhibiting Both Qi and Yin Deficiencies. JOURNAL OF CLINICAL RESEARCH, 2024, 41(5): 718-721.
2024, Vol. 41 
